Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: A meta-analysis

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 6, 2011, Pages 1039-1046

  Yang, Hui Jie ^a   Gu, Ying ^a   Chen, Chu ^a   Xu, Can ^a   Bao, Yi Xi ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

diagnosis; meta analysis; pro gastrin releasing peptide; small cell lung cancer

Indexed keywords

PROGASTRIN RELEASING PEPTIDE;

ARTICLE; CANCER DIAGNOSIS; CLINICAL EVALUATION; CLINICAL INDICATOR; DATA ANALYSIS SOFTWARE; DIAGNOSTIC VALUE; GOLD STANDARD; HUMAN; LUNG SMALL CELL CANCER; META ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

AREA UNDER CURVE; HUMANS; LUNG NEOPLASMS; PEPTIDE FRAGMENTS; PHOSPHOPYRUVATE HYDRATASE; RECOMBINANT PROTEINS; ROC CURVE; SMALL CELL LUNG CARCINOMA;

EID: 79958258577     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.161     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu JQ, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Kubuschok B, Passlick B, Izbicki JR. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol 1999;17:19-24. (Pubitemid 29022373)
3. Mountain CF. The international system for staging lung cancer. Semin Surg Oncol 2000;18:106-15. (Pubitemid 30090451)
4. Stupp R, Monnerat C, Turrisi AT, Perry MC, Leyvraz S. Small cell lung cancer: state of the art and future perspectives. Lung Cancer 2004;45:105-17. (Pubitemid 38757838)
5. Johnson BE, Crawford J, Downey RJ, Ettinger DS, Fossella F, Grecula JC, et al. National Comprehensive Cancer Network (NCCN): small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006;4:602-22. (Pubitemid 44265467)
6. Pujol JL, Quantin X, Jacot W, Boher JM, Grenier J, Lamy PJ. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 2003;39: 131-8. (Pubitemid 36173612)
7. Jorgensen LG, Osterlind K, Genolla J, Gomm SA, Hernandez JR. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer 1996;74:463-7. (Pubitemid 26254580)
8. Quoix E, Purohit A, Faller-Beau M, Moreau L, Oster JP, Pauli G. Comparative prognostic value of lactate dehydrogenase and neuronspecific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 2000;30:127-34.
9. Molina R, Filella X, Auge JM. ProGRP: a new biomarker for small cell lung cancer. Clinical Biochem 2004;37:505-11. (Pubitemid 38845013)
10. Plebani M, Basso D, Navaglia F, Paoli M, Tommasini A, Cipriani A. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer 1995;72:170-3.
11. Cook RM, Miller YE, Bunn PA Jr. Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. Semin Oncol 1993;17:73-141.
12. Nagalla SR, Gibson BW, Tang D, Reeve JR, Spindel ER. Gas-trin-releasing peptide (GRP) is not mammalian bombesin. J Biol Chem 1992;267:6916-22.
13. Schneider J, Philipp M, Velcovsky HG, Morr H, Katz N. Pro-gastrin-releasing peptide (ProGRP), neuron specic enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Anticancer Research 2003;23: 885-94.
14. Maruno K, Yamaguchi K, Abe K, Suzuki M, Saijo N, Mishima Y, et al. Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1989;49:629-32. (Pubitemid 19050327)
15. Miyake Y, Kodama T, Yamaguchi K. Pro-gastrin-releasing pep-tide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1994;54:2136-40. (Pubitemid 24138686)
16. Whiting P, Rutjes A, Reitsma J, Bossuyt P, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
17. Zamora J, Abraira V, Muriel A, Khan KS, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006;6:31.
18. Noriaki S, Satoshi T, Koichi M, Satoru W, Naoto F, Hideki H, et al. Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer. Oncology 1999;57:143-8.
19. Shibayama T, Ueoka H, Nishi K, Kiura K, Tabata M, Miyatake Y, et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small cell lung cancer (SCLC). Lung Cancer 2001;32:61-9. (Pubitemid 32224840)
20. Nisman B, Biran H, Ramu N, Heching N, Barak V, Peretz T. The diagnostic and prognostic value of ProGRP in lung cancer. Anticancer Res 2009;29:4827-32.
21. Rafael M, Josep MA, Xavier B, José ME, Nuria V, Ramón M, et al. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumor Biol 2009;30:121-9.
22. Yamaguchi K, Aoyagi K, Urakami K, Fukutani T, Maki N, Yamamoto S, et al. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Jpn J Cancer Res 1995;86:698-705.
23. Stieber P, Dienemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K, et al. Pro-gastrin-releasing peptide (ProGRP)-a useful marker in small cell lung carcinomas. Anticancer Res 1999;19:2673-8. (Pubitemid 29392436)
24. Oremek GM, Sauer EH, Bruzdziak TH. Value of tumor and inflammatory markers in lung cancer. Anticancer Res 2007;27: 1911-5. (Pubitemid 46954697)
25. Yang J, Li R, Li A. Clinical significance of ProGRP31-98 in patients with small-cell lung cancer. Zhonghua Zhong Liu Za Zhi 2000;22:216-8.
26. Koichi G, Tetsuro K, Fumihiko H, Kaoru K, Ryutaro K. Clinicopathologic characteristics of patients with non-small cell lung carcinoma with elevated serum progastrin-releasing pep-tide levels. Cancer 1998;82:1056-61.
27. Javier Z, Victor A, Alfonso M, Khalid K, Arri C. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006;6:1147-59.
28. Shields TW. Surgical therapy for carcinoma of the lung. Clin Chest Med 1993;14:121-47. (Pubitemid 23098993)
29. Takada M, Kusunoki Y, Masuda N, Matui K, Yana T, Ushijima S, et al. Pro-gastrin-releasing peptide (31-98) as a tumor marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. Br J Cancer 1996;73:1227-32. (Pubitemid 26162337)
30. Aoyagi K, Miyake Y, Urakami K, Kashiwakuma T, Hasegawa A, Kodama T, et al. Enzyme immunoassay of immunoreactive progastrin-releasing peptide (31-98) as tumor marker for small-cell lung carcinoma: development and evaluation. Clin Chem 1995;41:537-43.
31. Molina R, Alicarte J, Auge JM, Filella X, Ballesta AM. Pro-gastrin releasing peptide (ProGRP) in patients with benign and malignant diseases. Tumor Biol 2004;25:56-61. (Pubitemid 38822772)
32. Stieber P, Yamaguchi K. ProGRP enables diagnosis of small-cell lung cancer; physiology, pathobiology, technology and clinical applications. Washington AACC Press 2002;517-21.
33. Okusaka T, Eguchi K, Kasai T, Kurata T, Yamamoto N, Ohe Y, et al. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res 1997;3:123-7. (Pubitemid 27079454)